On-demand Webinar

Market Access for Groundbreaking Treatments – A Case Study of Pulsed Field Ablation (PFA)

Juliane Ray
Global Head of Medtech Strategy
Clarivate
Annette Boyle
Editor
BioWorld MedTech
Pankhil Ghandhi
Senior Team Lead, Medtech Insights
Clarivate
Dee Chaudhary
Principal Commercial Strategy Consulting
Clarivate
David Begley
MD, Clinical Director in Cardiology
Royal Papworth Hospital

Navigating the complexities of groundbreaking treatments can create headwinds. With innovations like Pulsed Field Ablation (PFA) at the forefront, challenges such as financial uncertainties, regulatory shifts, and global adoption become paramount. Join us for an insightful discussion on how global partners address these challenges, focusing on safety & efficacy, financial impacts, and clinical differentiation in areas where baseline data is scarce. Background on PFA: Pulsed Field Ablation (PFA) is a groundbreaking nonthermal energy source that is rapidly transforming atrial fibrillation (AF) treatment, affecting up to 38 million people worldwide. Unlike traditional heat or cold methods, PFA uses high-voltage electrical fields in microseconds for precise cell necrosis, marking a significant advancement in cardiology.